Status:
RECRUITING
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers
Lead Sponsor:
argenx
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body....
Eligibility Criteria
Inclusion
- Is at least the local legal age of consent for clinical studies and is aged 18 to 65 years, inclusive, when signing the ICF
- Is a female of nonchild bearing potential (either postmenopausal or surgically sterilized) or a male
- Has a body weight between 50 and 100 kg and a BMI between 18 and 30.5 kg/m\^2, inclusive
Exclusion
- Has any current or past clinically meaningful medical or psychiatric condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
- Has a clinically meaningful abnormality detected on ECG recording regarding either rhythm or conduction
Key Trial Info
Start Date :
April 11 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06968338
Start Date
April 11 2025
End Date
June 30 2026
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Altasciences
Montreal, Canada, QC H3P 3P1